Earnings History Data for Incyte (INCY) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
29-04-2025	PM		INCY	Incyte	11,412	0.89	1.03	0.00	Incyte Non-GAAP EPS of $1.16 beats by $0.11, revenue of $1.05B beats by $53.43M [4/29/2025 7:07 AM]	60.40	0.88 (1.48%)	61.00	1.48 (2.49%)	50.35 - 83.95	1,854,237	1,630,000	9,017
Incyte Q1 2025 Earnings Preview [4/28/2025 2:29 PM] Incyte Non-GAAP EPS of $1.16 beats by $0.11, revenue of $1.05B beats by $53.43M [4/29/2025 7:07 AM] Incyte raises 2025 Jakafi revenue guidance to $3B amid strong Q1 growth [4/29/2025 12:53 PM] Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs [2025-04-29 07:00AM] Incyte (INCY) Q1 Earnings Report Preview: What To Look For [Apr-28-25 03:04AM]
10-02-2025	PM		INCY	Incyte Corporation	14,440	1.09	1.29	0.82	Incyte Non-GAAP EPS of $1.43 misses by $0.12, revenue of $1.18B beats by $30M [2/10/2025 7:01 AM]	68.34	-5.79 (-7.81%)	74.00	-0.13 (-0.18%)	50.35 - 83.95	3,203,609	1,380,000	19,667
Incyte Non-GAAP EPS of $1.43 misses by $0.12, revenue of $1.18B beats by $30M [2/10/2025 7:01 AM] Earnings Snapshot: Incyte reports Q4 revenue beat, profit misses estimate; issues FY25 outlook [2/10/2025 7:14 AM] Incyte outlines 2025 milestones with projected $1B in incremental revenue contributions [2/10/2025 11:52 AM] Incyte stock falls 6% amid Q4 earnings, 2025 forecast [2/10/2025 12:09 PM] Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones [2025-02-10 07:00AM] Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Feb-07-25 04:30PM] Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4 [2025-02-10 07:30AM] Incyte: Q4 Earnings Snapshot [2025-02-10 07:23AM]
29-10-2024	PM		INCY	Incyte Corporation	12,530	0.73	0.96	0.91	Incyte Non-GAAP EPS of $1.07 misses by $0.03, revenue of $1.14B beats by $60M [10/29/2024 7:06 AM]	73.50	7.81 (11.89%)	67.48	1.79 (2.72%)	50.27 - 74.07	3,628,776	1,130,000	1,092
Incyte Q3 2024 Earnings Preview [10/28/2024 2:03 PM] Incyte Non-GAAP EPS of $1.07 misses by $0.03, revenue of $1.14B beats by $60M [10/29/2024 7:06 AM] Incyte stock jumps 8% on Q3 revenue beat, raised guidance [10/29/2024 10:22 AM] Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs [2024-10-29 07:00AM]
30-07-2024	PM		INCY	Incyte Corporation	15,400	-2.03	0.97	0.77	Incyte Non-GAAP EPS of -$1.82 misses by $2.93, revenue of $1.04B beats by $30M [7/30/2024 7:07 AM]	67.84	-0.75 (-1.09%)	69.00	0.41 (0.60%)	50.27 - 70.36	3,991,885	2,000,000	37,585
Incyte Q2 2024 Earnings Preview [7/29/2024 1:40 PM] Incyte Non-GAAP EPS of -$1.82 misses by $2.93, revenue of $1.04B beats by $30M [7/30/2024 7:07 AM] Incyte drops 5 clinical drug candidates following a strategic review [7/30/2024 1:13 PM]
30-04-2024	PM		INCY	Incyte Corporation	11,490	0.38	0.72	0.18	Incyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75M [4/30/2024 7:03 AM]	52.04	-0.52 (-0.99%)	50.00	-2.56 (-4.87%)	50.27 - 75.74	3,692,040	2,020,000	39,400
Incyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75M [4/30/2024 7:03 AM] Incyte Q1 2024 Earnings Preview [4/29/2024 11:44 AM]
13-02-2024	PM		INCY	Incyte Corporation	12,920	0.82	1.03	0.44	Incyte reports mixed Q4 results; initiates FY24 outlook [2/13/2024 7:10 AM]	59.35	1.51 (2.61%)	58.98	1.14 (1.97%)	50.27 - 80.22	2,995,102	1,660,000	8,536
Incyte Q4 2023 Earnings Preview [2/12/2024 11:41 AM] Incyte reports mixed Q4 results; initiates FY24 outlook [2/13/2024 7:10 AM]
31-10-2023	PM		INCY	Incyte Corporation	12,160	0.91	0.90	0.44	Incyte Non-GAAP EPS of $1.10 beats by $0.04, revenue of $919M misses by $44.09M [10/31/2023 7:01 AM]	53.98	1.82 (3.49%)	52.16	0.0 (0.00%)	50.27 - 86.29	3,124,853	1,740,000	3,006
Incyte Q3 2023 Earnings Preview [10/30/2023 12:33 PM] Incyte Non-GAAP EPS of $1.10 beats by $0.04, revenue of $919M misses by $44.09M [10/31/2023 7:01 AM]
01-08-2023	PM		INCY	Incyte Corporation	14,070	0.77	0.69	0.85	Incyte Non-GAAP EPS of $0.99 beats by $0.12, revenue of $954.61M beats by $44.2M [8/1/2023 7:04 AM]	63.68	-0.04 (-0.06%)	66.30	2.58 (4.05%)	60.56 - 86.29	1,984,613	1,500,000	19,940
Replimune, Incyte to collaborate on squamous cell carcinoma combo [7/31/2023 5:35 PM] Incyte Q2 2023 Earnings Preview [7/31/2023 1:10 PM] Incyte Non-GAAP EPS of $0.99 beats by $0.12, revenue of $954.61M beats by $44.2M [8/1/2023 7:04 AM]
02-05-2023	PM	7:00 AM ET (May 2)	INCY	Incyte Corporation	16,420	0.18	0.59	0.40	Incyte Non-GAAP EPS of $0.37 misses by $0.37, revenue of $808.67M misses by $49.92M [5/2/2023 7:02 AM]	70.06	-5.28 (-7.01%)	69.00	-6.34 (-8.42%)	65.07 - 86.29	3,904,514	2,000,000	11,506
Incyte Non-GAAP EPS of $0.37 misses by $0.37, revenue of $808.67M misses by $49.92M [5/2/2023 7:02 AM] Incyte trades lower as profit falls, tightens Jakafi outlook on strong Q1 sales [5/2/2023 7:46 AM]
07-02-2023	PM	7:00 AM ET (Feb 7)	INCY	Incyte Corporation	18,800	0.44	0.45	-0.07	Incyte Non-GAAP EPS of $0.62 beats by $0.05, revenue of $926.7M beats by $46.45M [2/7/2023 7:01 AM]	80.82	-3.54 (-4.20%)	86.00	1.64 (1.94%)	65.07 - 86.29	3,718,253	1,520,000	38,711
Incyte Non-GAAP EPS of $0.62 beats by $0.05, revenue of $926.7M beats by $46.45M [2/7/2023 7:01 AM] Incyte down 5% following quarterly earnings as Street reacts to 2023 Jakafi estimates [2/7/2023 12:26 PM]
01-11-2022	PM	7:00 AM ET (Nov 1)	INCY	Incyte Corporation	16,590	0.44	0.54	1.00	Incyte Non-GAAP EPS of $0.60 misses by $0.10, revenue of $823.03M misses by $20.62M [11/1/2022 7:03 AM]	76.99	2.65 (3.56%)	75.02	0.68 (0.91%)	61.91 - 84.86	3,658,542	1,720,000	10,342
Incyte Non-GAAP EPS of $0.60 misses by $0.10, revenue of $823.03M misses by $20.62M [11/1/2022 7:03 AM] Incyte rises 5% as company raises Jakafi net product revenues [11/1/2022 12:32 PM] Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs [Nov-01-22 07:00AM] Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More [Oct-31-22 04:07PM]
02-08-2022	PM	7:00 AM ET (Aug 2)	INCY	Incyte Corporation	17,920	0.85	0.61	0.65	Incyte Non-GAAP EPS of $1.01 beats by $0.27, revenue of $911.4M beats by $93.15M [8/2/2022 7:02 AM]	72.51	-4.89 (-6.32%)	75.15	-2.25 (-2.91%)	61.91 - 84.86	2,699,478	1,330,000	16,021
Incyte Q2 2022 Earnings Preview [8/1/2022 1:04 PM] Incyte Non-GAAP EPS of $1.01 beats by $0.27, revenue of $911.4M beats by $93.15M [8/2/2022 7:02 AM] Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6% [8/2/2022 10:36 AM] Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More [Aug-01-22 01:59PM] Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs [Aug-02-22 07:00AM]
03-05-2022	PM	7:00 AM ET (May 3)	INCY	Incyte	16,688	0.40	0.57	0.00	Incyte Non-GAAP EPS of $0.55 misses by $0.14, revenue of $733.24M misses by $20.3M; reaffirms FY22 guidance [5/3/2022 7:12 AM]	77.24	1.18 (1.56%)	76.00	-0.05 (-0.07%)	61.91 - 88.26	1,660,171	1,594,833	241
Incyte Q1 consensus EPS, revenue estimates up Y/Y [5/2/2022 11:03 AM] Incyte Non-GAAP EPS of $0.55 misses by $0.14, revenue of $733.24M misses by $20.3M; reaffirms FY22 guidance [5/3/2022 7:12 AM] Incyte Q1 net income drops 17% as operating expenses soar [5/3/2022 12:31 PM] Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More [May-02-22 03:55PM] Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs [May-03-22 07:00AM] Incyte (INCY) Lags Q1 Earnings and Revenue Estimates [May-03-22 08:25AM] Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates [May-03-22 11:53AM] Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance [May-03-22 02:05PM]
08-02-2022	PM	7:00 AM ET (Feb 8)	INCY	Incyte Corporation	16,140	-0.07	0.65	0.73	IncyteEPS of $0.10, revenue of $862.5M beats by $49.12M [2/8/2022 7:02 AM]	70.06	-3.29 (-4.49%)	71.00	-2.35 (-3.20%)	61.91 - 94.50	2,812,729	1,790,000	30,077
Incyte Q4 2021 Earnings Preview [2/7/2022 11:39 AM] IncyteEPS of $0.10, revenue of $862.5M beats by $49.12M [2/8/2022 7:02 AM] Incyte beats on top line buoyed by increase in Jakafi revenues [2/8/2022 8:26 AM] Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH [Feb-07-22 09:53AM] McCarthy Asset Management, Inc. Buys ARK Innovation ETF, Parker Hannifin Corp, Adient PLC, ... [Feb-07-22 09:38AM] Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs [Feb-08-22 07:00AM] The SEC is pushing the limits of insider trading enforcement [Feb-08-22 06:44AM] Incyte (INCY) Q4 Earnings Miss, Sales Beat on Jakafi, Royalties [Feb-08-22 11:01AM] Why Are Incyte Shares Trading Lower Today? [Feb-08-22 12:24PM]
02-11-2021	PM	7:00 AM ET (Nov 2)	INCY	Incyte Corporation	14,520	1.00	0.52	0.03	Incyte EPS beats by $0.43, beats on revenue [11/2/2021 7:11 AM]	63.48	-5.87 (-8.46%)	63.48	0.0 (0.00%)	61.91 - 101.47	4,984,541	1,520,000	9,462
Incyte Q3 2021 Earnings Preview [11/1/2021 12:37 PM] FDA accepts to review Incyte's NDA for parsaclisib [11/1/2021 7:38 AM] Incyte EPS beats by $0.43, beats on revenue [11/2/2021 7:11 AM] Incyte shares fall despite Jakafi powered Q3 earnings beat [11/2/2021 10:01 AM] Data from Incytes Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting [Nov-01-21 09:16AM] Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas [Nov-01-21 07:00AM] Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs [Nov-02-21 07:00AM] McKesson Posts Better Than Expected Q2 Earnings; Raises FY22 EPS Outlook Again [Nov-02-21 06:34AM] Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical [Nov-02-21 08:50AM] Incyte (INCY) Q3 Earnings and Revenues Beat Estimates [Nov-02-21 08:35AM] Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow [Nov-02-21 09:24AM] Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript [Nov-02-21 12:00PM]
03-08-2021	PM	7:00 AM ET (Aug 3)	INCY	Incyte Corporation	17,010	0.65	0.54	1.04	Incyte EPS beats by $0.06, beats on revenue [8/3/2021 7:07 AM]	77.96	-0.51 (-0.65%)	77.70	-0.77 (-0.98%)	75.52 - 102.61	1,360,307	1,310,000	2,351
Incyte Q2 2021 Earnings Preview [8/2/2021 1:44 PM] Lilly, Incyte's baricitinib reduces deaths among COVID-19 patients on mechanical ventilation [8/3/2021 6:55 AM] Incyte EPS beats by $0.06, beats on revenue [8/3/2021 7:07 AM] Incyte tops Q1 forecast; Jakafi revenue outlook lowered [8/3/2021 7:58 AM] Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More [Aug-02-21 09:36AM] Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation [Aug-03-21 06:00AM] UPDATE 1-Lilly's COVID-19 drug reduces death risk in patients on mechanical ventilation [Aug-03-21 06:31AM] Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs [Aug-03-21 07:00AM] Incyte (INCY) Q2 Earnings and Revenues Beat Estimates [Aug-03-21 08:25AM] Incyte (INCY) Q2 Earnings & Sales Beat on Solid Jakafi Growth [Aug-03-21 12:43PM] Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript [Aug-03-21 04:30PM]
04-05-2021	PM	7:00 AM ET (May 4)	INCY	Incyte Corporation	18,670	0.50	0.42	-3.05	Incyte EPS beats by $0.03, misses on revenue; reaffirms guidance [5/4/2021 7:03 AM]	81.03	-4.49 (-5.25%)	81.03	0.0 (0.00%)	75.52 - 110.36	2,373,938	880,000	14,418
Incyte EPS beats by $0.03, misses on revenue; reaffirms guidance [5/4/2021 7:03 AM] Incyte posts mixed Q1 results, reaffirms guidance [5/4/2021 8:07 AM] Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 [May-03-21 08:00AM] Is a Surprise Coming for Incyte (INCY) This Earnings Season? [May-03-21 07:54AM] Incyte Corp. to Host Earnings Call [May-04-21 06:15AM] Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs [May-04-21 07:00AM] Incyte (INCY) Tops Q1 Earnings Estimates [May-04-21 08:25AM] Incyte Corp (INCY) Q1 2021 Earnings Call Transcript [May-04-21 12:30PM] Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi [May-04-21 01:47PM]
09-02-2021	PM	7:00 AM ET (Feb 9)	INCY	Incyte Corporation	19,760	0.73	0.64	0.50	Incyte EPS beats by $0.16, beats on revenue [2/9/2021 7:01 AM]	89.51	-4.11 (-4.39%)	94.50	0.88 (0.94%)	62.48 - 110.36	1,184,102	1,097,613	8,168
Incyte EPS beats by $0.16, beats on revenue [2/9/2021 7:01 AM] Incyte Q4 2020 Earnings Preview [2/8/2021 12:02 PM] Incyte Q4 topline up 36%, posts 2021 forecast [2/9/2021 7:54 AM] What's Behind Incyte's Better-Than-Expected Q4 Earnings [Feb-09-21 02:00PM] Incyte Corp (INCY) Q4 2020 Earnings Call Transcript [Feb-09-21 01:30PM] Recap: Incyte Q4 Earnings [Feb-09-21 07:13AM] Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs [Feb-09-21 07:00AM]
05-11-2020	PM	7:00 AM ET (Nov 5)	INCY	Incyte Corporation	18,580	0.03	0.47	0.62	Incyte EPS misses by $0.53, misses on revenue [11/5/2020 7:05 AM]	84.65	-6.56 (-7.19%)	84.65	0.0 (0.00%)	62.48 - 110.36	1,930,638	986,819	18,618

04-08-2020	PM	7:00 AM ET (Aug 4)	INCY	Incyte Corporation	21,470	1.04	0.68	0.56	Incyte EPS beats by $0.37, beats on revenue [8/4/2020 7:02 AM]	98.45	-3.34 (-3.28%)	102.49	0.70 (0.69%)	62.48 - 110.36	943,186	1,113,492	10,963

05-05-2020	PM	7:00 AM ET (May 5)	INCY	Incyte Corporation	21,110	-3.05	0.31	0.47	Incyte EPS misses by $2.50, beats on revenue [5/5/2020 7:06 AM]	99.31	-1.68 (-1.66%)	99.58	-1.41 (-1.40%)	62.48 - 104.81	549,209	1,718,626	6,482